MANNKIND CORP Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
MANNKIND CORP (MNKD) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $5.76 per share as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-08-05
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $5.76.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $5.75.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $5.80; Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value as first filed $5.82.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $5.49.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value as first filed |
|---|---|---|
| 2026-06-30 | $5.76 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $5.75 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $5.80 10-Q · filed 2026-08-05 | $5.82 10-K · filed 2026-02-26 |
| 2024-12-31 | $5.49 10-K · filed 2026-02-26 | |
| 2023-12-31 | $4.61 10-K · filed 2025-02-26 | |
| 2022-12-31 | $3.65 10-K · filed 2024-02-27 | |
| 2021-12-31 | $3.40 10-K · filed 2023-02-23 | $3.77 10-K · filed 2022-02-24 |
| 2020-12-31 | $2.20 10-K · filed 2022-02-24 | |
| 2019-12-31 | $2.16 10-K · filed 2021-02-25 | |
| 2018-12-31 | $3.72 10-K · filed 2020-02-25 | $3.71 10-K · filed 2019-02-26 |
| 2017-12-31 | $4.08 10-K · filed 2019-02-26 | |
| 2016-12-31 | $8.40 10-K · filed 2018-02-27 | |
| 2015-12-31 | $24.25 10-K · filed 2017-03-16 | $4.85 10-K · filed 2016-03-15 |
| 2014-12-31 | $5.20 10-K · filed 2016-03-15 | |
| 2013-12-31 | $3.90 10-K · filed 2015-03-02 | |
| 2012-12-31 | $3.73 10-K · filed 2014-03-03 | |
| 2011-12-31 | $4.47 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |